SCHEMBL10050490

SCHEMBL10050490

Cc1ccc(S(=O)(=O)n2ccc(CC(=O)NCCCOc3ccc(-c4c5nc(c(-c6ccncc6)c6ccc([nH]6)c(-c6ccncc6)c6nc(c(-c7ccncc7)c7ccc4[nH]7)C=C6)C=C5)cc3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 1/20 0.37
▸ ENPP2 Q13822 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ GRM4 Q14833 1/20 0.34
▸ TOP1 P11387 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ADAMTS4 O75173 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10050492 0.78 TOP1 (0.41) TERTENPP2ABCG2LMNATOP1
SCHEMBL10050505 0.76 MAPT (0.41) ABCG2TOP1KMT2AALDH1A1MAPT
SCHEMBL12265142 0.73 TOP1 (0.41) ENPP2ABCG2LMNATOP1ALDH1A1
SCHEMBL10050506 0.69 TERT (0.46) TERTENPP2ABCG2TOP1MAPT
SCHEMBL10050512 0.67 TERT (0.43) TERTABCG2TOP1KMT2AALDH1A1
SCHEMBL10050508 0.67 MAPT (0.43) ABCG2ALDH1A1MAPT
SCHEMBL6493302 0.67 TOP1 (0.70) TERTENPP2ABCG2TOP1
SCHEMBL16560468 0.67 TOP1 (0.70) TERTENPP2ABCG2TOP1
SCHEMBL6494256 0.67 TOP1 (0.70) TERTENPP2ABCG2TOP1
SCHEMBL6030672 0.67 TOP1 (0.70) TERTENPP2ABCG2TOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 — — US disclosed
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 — — US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 — — US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 — — US disclosed
WO-2007051947-A1 NOVEL ELECTROPOLYMERISABLE MONOMERS WHICH ARE SOLUBLE IN AN AQUEOUS SOLUTION AND COMPRISE A METALLOPORPHYRINE BIOMERIEUX (FR) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin EPS15, PPOX, ACR TERT 1074/4885ENPP2 1999/4885ABCG2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback